A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms

Not Applicable

Completed

• Conditions: Acne
• Interventions: Other: EQ Exfoliating Cleanser; Other: EQ Gel; Other: EQ Moisturizer

• Registration Number: NCT06122467
• Lead Sponsor: Menning Labs

Brief Summary

This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-02
• Study First Submitted: 2023-11-02
• Study First Submitted QC: 2023-11-02
• Study First Posted: 2023-11-08
• Primary Completion: 2023-12-31
• Study Completion: 2023-12-31
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-18
• Last Update Posted: 2024-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Be aged between 18-45.
• Anyone who has acne prone skin and a history of recurring acne.
• Has visible acne at enrollment.
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
• Have a digital camera or smartphone to take photos of the face.

Exclusion Criteria

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
• Anyone currently using a prescription skin product.
• Anyone who is unwilling to stop using the current acne supplements they are taking.
• Anyone with known severe allergic reactions.
• Any women who are pregnant, breastfeeding or attempting to become pregnant.
• Anyone unwilling to follow the study protocol.
• Anyone who identifies as having sensitive skin.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Test group: EQ Product Line	EQ Exfoliating Cleanser	The following regimen should be completed in both the morning and the evening. The order of use is: Cleanser Gel Moisturizer.
Test group: EQ Product Line	EQ Gel	The following regimen should be completed in both the morning and the evening. The order of use is: Cleanser Gel Moisturizer.
Test group: EQ Product Line	EQ Moisturizer	The following regimen should be completed in both the morning and the evening. The order of use is: Cleanser Gel Moisturizer.

Primary Outcome Measures

Name	Time	Method
Change in the appearance of facial skin acne. [Timeframe: Baseline to Day 56]	56 days	Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.; Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
Changes in skin clarity i.e. reduction in acne or associated blemishes. [Timeframe: Baseline to Day 56]	56 days	Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.; Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

Secondary Outcome Measures

Name	Time	Method
Changes in overall skin health. [Timeframe: Baseline to Day 56]	56 days	Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.; Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
Changes in skin redness. [Timeframe: Baseline to Day 56]	56 days	Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.; Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
Changes in skin smoothness. [Timeframe: Baseline to Day 56]	56 days	Assessed by surveys completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").
Changes in facial skin irritation. [Timeframe: Baseline to Day 56]	56 days	Surveys will be completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").
Changes in skin texture. [Timeframe: Baseline to Day 56]	56 days	Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.; Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

Trial Locations

Locations (1)

Citruslabs; 🇺🇸 Santa Monica, California, United States